

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021

Nerviano, 29 September 2021_NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue.

The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts and members of Pharma Tech Outlook's editorial board, NMS Group has come on top in terms of its ability to innovate in drug R&D process, and to meet client requirements, through support and customization.

"We're delighted to be recognized as a leader in changing drug development landscape with oncology innovations," stated Nanding Zhao, CEO of NMS Group. "We will keep taking Oncology forward through our intra-subsidary collaborations between Nerviano Medical Sciences, Accelera and NerPharMa. Our integrated and fully fledged R&D organization will keep developing innovative new molecular entities (NMEs) and develop them to drugs with global partners. We will also explore new areas of sciences and technologies to strengthen future development of the company."

Read the full article [here](#).

###

About Pharma Tech Outlook

Published from Fremont, California, Pharma Tech Outlook is monthly publication bringing forth real world solutions, news and insights into the pharmaceutical and drug development space. With industry leading contributors Pharma Tech Outlook brings together a unique network of peers who share experiences, ideas, and techniques with each other and the larger scientific community. A panel of experts and members of Pharma Tech Outlook's editorial board selected and finalized the "Top 10 Drug Discovery and Development Solution Providers in Europe 2021" and shortlisted the best vendors and consultants. For more information: <https://www.pharmatechoutlook.com/>

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the



NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERERA

NERPHARMA

SIMIS

antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelerera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it